
EAP Program Authorized for ALS Agent SPG302, PTC518 Meets Primary End Point, Capricor Completes Mid-Cycle Review for ...
WATCH TIME: 4 minutes Welcome to this special edition of Neurology News Network. I'm Marco Meglio. According to a new announcement, the FDA has authorized Spinogenix’s expanded access program (EAP) for its investigational amyotrophic lateral sclerosis …